BioCentury
ARTICLE | Clinical News

Novo Nordisk reports data for hemophilia A compound

March 20, 2014 12:48 AM UTC

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) reported data on Wednesday from the Phase III pathfinder 2 trial evaluating IV N8-GP ( NN7088) to treat hemophilia A. In the trial, prophylactic treatment with N8-GP (n=175) every fourth day led to a median annualized bleeding rate of 1.3 episodes. On-demand treatment with N8-GP when bleeding occurred led to a median annualized bleeding rate of 30.9 episodes (n=11). Novo Nordisk said one patient in the prophylactic treatment arm developed a Factor Vlll (FVIII) inhibitor, which it said was consistent with expectations for the population. The open-label, international trial enrolled 186 hemophilia A patients 12 years of age and older who were previously treated with other FVIII products. ...